FDA refuses to file T-DM1 BLA

ImmunoGen Inc. (NASDAQ:IMGN) fell $3.23 (39%) to $5.16 on Friday after FDA refused to file a BLA from partner Genentech Inc. for trastuzumab-DM1 ( T-DM1)

Read the full 259 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE